Ymmunobio Signs Transfer Ownership Agreement with Nagoya University for NPTXR antibodiesJan 31, 2023Research indicates that NPTXR may have utility for treatment of gastro-intestinal cancers.Read more here: https://www.prnewswire.com/news-releases/ymmunobio-signs-transfer-ownership-agreement-with-nagoya-university-for-nptxr-antibodies-301733781.html
Drug Discovery & DevelopmentJan 31, 2023Ymmunobio get ownership rights to NPTXR antibodies. Read more here:https://www.drugdiscoverytrends.com/ymmunobio-gets-ownership-rights-to-nptxr-antibodies/
Fierce Biotech: Appointment of Michel JanicotJan 13, 2023Michel Janicot will serve in the newly created position of chief development officer.https://www.fiercebiotech.com/biotech/chutes-ladders-novavax-ceo-erck-bids-adieu-after-12-years-overseeing-covid-vax-development
